| Drug General Information |
| Drug ID |
D05WTZ
|
| Former ID |
DIB008216
|
| Drug Name |
Galarubicin
|
| Synonyms |
DA-125; Metalloprotease inhibitors (cancer), Dong-A
|
| Drug Type |
Small molecular drug
|
| Indication |
Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48]
|
Discontinued in Phase 2 |
[1]
|
|---|
| Company |
Dong-A Pharmaceutical Co Ltd
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C30H32FNO13
|
| Canonical SMILES |
c12c(C(=O)c3c(C1=O)cccc3OC)c(c1c(c2O)C[C@](C[C@@H]1O[C@<br />H]1[C@@H]([C@@H]([C@@H]([C@@H](O1)C)O)O)F)(C(=O)COC(=O)<br />CCN)O)O
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
MMP-9 |
Target Info |
Inhibitor |
[2]
|
|---|
| 72 kDa type IV collagenase |
Target Info |
Inhibitor |
[2]
|
|
KEGG Pathway
|
TNF signaling pathway
|
|
Leukocyte transendothelial migration
|
|
Estrogen signaling pathway
|
|
Hepatitis B
|
|
Pathways in cancer
|
|
Transcriptional misregulation in cancer
|
|
Proteoglycans in cancer
|
|
MicroRNAs in cancer
|
|
Bladder cancerhsa04670:Leukocyte transendothelial migration
|
|
GnRH signaling pathway
|
|
Bladder cancer
|
|
NetPath Pathway
|
ID Signaling Pathway
|
|
TWEAK Signaling Pathway
|
|
Leptin Signaling Pathway
|
|
TNFalpha Signaling PathwayNetPath_22:Leptin Signaling Pathway
|
|
TCR Signaling Pathway
|
|
PANTHER Pathway
|
Alzheimer disease-presenilin pathway
|
|
Plasminogen activating cascade
|
|
CCKR signaling map STP00004:Alzheimer disease-presenilin pathway
|
|
Pathway Interaction Database
|
LPA receptor mediated events
|
|
Plasma membrane estrogen receptor signaling
|
|
Osteopontin-mediated events
|
|
Validated transcriptional targets of AP1 family members Fra1 and Fra2
|
|
Validated targets of C-MYC transcriptional activation
|
|
CXCR4-mediated signaling events
|
|
amb2 Integrin signaling
|
|
Syndecan-4-mediated signaling events
|
|
AP-1 transcription factor network
|
|
Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling
|
|
Syndecan-1-mediated signaling events
|
|
Regulation of nuclear beta catenin signaling and target gene transcription
|
|
FGF signaling pathwaylysophospholipid_pathway:LPA receptor mediated events
|
|
Angiopoietin receptor Tie2-mediated signaling
|
|
Direct p53 effectors
|
|
ATF-2 transcription factor network
|
|
FOXM1 transcription factor network
|
|
Syndecan-2-mediated signaling events
|
|
Reactome
|
Collagen degradation
|
|
Degradation of the extracellular matrix
|
|
Activation of Matrix Metalloproteinases
|
|
Assembly of collagen fibrils and other multimeric structures
|
|
EPH-ephrin mediated repulsion of cellsR-HSA-1442490:Collagen degradation
|
|
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
|
|
EPH-ephrin mediated repulsion of cells
|
|
WikiPathways
|
Endochondral Ossification
|
|
IL1 and megakaryotyces in obesity
|
|
Mammary gland development pathway - Involution (Stage 4 of 4)
|
|
Activation of Matrix Metalloproteinases
|
|
Degradation of collagen
|
|
Spinal Cord Injury
|
|
AGE/RAGE pathway
|
|
TWEAK Signaling Pathway
|
|
Angiogenesis
|
|
Osteopontin Signaling
|
|
Matrix MetalloproteinasesWP2769:Activation of Matrix Metalloproteinases
|
|
Matrix Metalloproteinases
|
| References |
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004410) |
|---|
| REF 2 | Inhibitory effect of DA-125, a new anthracyclin analog antitumor agent, on the invasion of human fibrosarcoma cells by down-regulating the matrix metalloproteinases. Biochem Pharmacol. 2005 Dec 19;71(1-2):21-31. Epub 2005 Nov 2. |
|---|
